The immune system has evolved mechanisms to recognize and eliminate threats, as well as to protect against self-destruction. Tolerance to self-antigens is generated through two fundamental mechanisms: (a) elimination of self-reactive cells in the thymus during selection and (b) generation of a variety of peripheral regulatory cells to control self-reactive cells that escape the thymus. It is becoming increasing apparent that a population of thymically derived CD4 + regulatory T cells, exemplified by the expression of the IL-2Rα chain, is essential for the maintenance of peripheral tolerance. Recent work has shown that the forkhead family transcription factor Foxp3 is critically important for the development and function of the regulatory T cells. Lack of Foxp3 leads to development of fatal autoimmune lymphoproliferative disease; furthermore, ectopic Foxp3 expression can phenotypically convert effector T cells to regulatory T cells. This review focuses on Foxp3 expression and function and highlights differences between humans and mice regarding Foxp3 regulation. 
INTRODUCTION
Immunological tolerance to self-antigens is a tightly regulated process. A primary mechanism for self-tolerance is deletion of selfreactive cells in the thymus. However, this mechanism is not perfect, and autoreactive clones do escape into the periphery. Tolerance is maintained in the periphery through a variety of mechanisms, including a population of regulatory T cells that actively suppress the function of autoreactive T cells. These T cells, identified by their expression of CD4, the IL-2Rα chain (CD25), and the forkhead family transcription factor Foxp3, are know as regulatory T cells, or Tregs. They have the ability to inhibit the development of autoimmunity when transferred into the appropriate host. Recent work has shown that the forkhead/winged-helix protein Foxp3 is expressed predominantly in Tregs and is both necessary and sufficient for their development and function.
Several excellent reviews have been written recently on the development and function of CD4 + CD25 + Tregs (1-5). Thus, this review does not directly address these issues. Instead, I review what is known concerning the expression and function of Foxp3, which is critical for the development and function of Tregs, especially in the mouse. Although the overall importance of Foxp3 is obvious from the phenotype of humans and mice that lack this protein, very little is actually known about how it functions and what controls its expression. This review highlights the similarities and differences in Foxp3 expression function in human and mouse, with an emphasis on the differences.
IDENTIFICATION AND CHARACTERIZATION OF MOUSE Foxp3

Characterization of Scurfy (sf ) Mutant Mice
The scurfy (sf ) mutation arose spontaneously in the partially inbred MR strain in 1949 at the Oak Ridge National Laboratory. Subsequent studies showed the gene to be X-linked, with only X sf /Y males affected (here, these mice are referred to as sf/Y). Grossly, affected sf/Y males exhibit several external markers of disease, including ear thickening; scaling of the ears, eyelids, feet, and tail; and severe runting. Internally, the mice exhibit lymphadenopathy, splenomegaly, hepatomegaly, and massive lymphocytic infiltrates in the skin and liver. These lesions closely resemble those seen in a graft-versus-host reaction. Mice display anemia and have a positive direct Coombs's test, but they lack evidence of autoantibodies against double-strand DNA or small ribonuclear protein antigens (6). Taken together, these gross assessments suggest that sf is a mutation that causes an autoimmune-like disease in affected animals. In this regard, sf/Y mice resemble mice bearing targeted mutations in the ctla-4 or tgf-β1 genes. These mice die at approximately three weeks of age from a massive lymphoproliferative disease, with peripheral lymphocyte levels up to 20-fold greater than normal mice (7, 8) .
Phenotypically, scurfy disease is most consistent with a diagnosis of autoimmune lymphoproliferative disease. This idea is supported by the finding that mice expressing a transgenic T cell receptor (TCR) survive significantly longer in the absence of antigen stimulation (60 days compared with 20-24 days) and that they live a normal lifespan and are free of sf disease when they are also rag-2-null (sf/ova/rag mice). Finally, T cells from sf/Y mice display reduced sensitivity to inhibitors of T cell activation, suggesting that TCR signaling is dysregulated in sf/Y mice. Taken together, these data suggest the sf disease results from an inability to properly regulate antigen-driven T cell activation.
One of the in vitro hallmarks of sf disease is the spontaneous proliferation and cytokine production exhibited by T cells isolated from sf/Y mice. Initial studies showed that cytokine production in vitro by ConAstimulated sf/Y splenocytes was greatly elevated (9). More detailed studies, using purified CD4 + T cells from sf/Y and normal littermate control (NLC) mice, showed that these cells were capable of proliferation and cytokine production when examined directly ex vivo. However, to achieve maximal T cell stimulation, TCR engagement was required, suggesting that the defect in sf mice is not nonspecific T cell activation. CD4 + T cells from sf/Y mice were hyperresponsive to TCR-mediated signals, responding to TCR engagement with crosslinking antibodies at concentrations 10-fold lower than their wild-type counterparts (10). Consistent with the increased expression of costimulatory molecules in sf/Y mice, CD4
+ T cells from these mice responded to CD28 crosslinking (10). Recent studies have shown that the transcription factors NFAT and AP-1 are constitutively activated in CD4
+ T cells from sf/Y mice (11). Also, these same T cells have a marked decrease in their sensitivity to cyclosporin A, with an IC 50 15-fold higher than NLCderived T cells (10). Both observations are indicative of an alteration in TCR-mediated signal transduction in CD4 + T cells from sf/Y mice and may account for the increased cytokine production exhibited by these cells.
Consequence of Foxp3 Expression on CD4
+ T Cell Function
The gene responsible for scurfy disease was molecularly cloned using a standard positional cloning approach (12). Sequence analysis of the cloned gene showed that it encoded a novel member of the forkhead family of transcriptional regulators, Foxp3 (see below for more details). To verify this gene as the gene responsible for the scurfy mutation, transgenic mice were generated using a cosmid clone containing mouse Foxp3. When bred to sf/Y mice, expression of the transgene was capable of rescuing the mice from scurfy disease and demonstrated that a mutation in Foxp3 was indeed responsible for the scurfy phenotype (12). The Foxp3 transgenic mice (referred to as Foxp3-Tg hereafter) also provided a model NFAT: nuclear factor of activated T cells system for examining the in vivo consequences of Foxp3 expression. Several individual Foxp3-Tg lines were established, each with differing levels of transgene expression (12, 13). Each of these lines, when bred into an otherwise wild-type background, resulted in a reduction in peripheral CD4 + and CD8
+ T cell numbers, with the extent of the reduction directly correlated with transgene copy number and expression (12). However, thymic cellularity was unaffected, as was positive and negative selection. Thus, levels of Foxp3 determined the number of peripheral T cells, while having little effect on the number and differentiation of thymocytes.
To examine the function of T cells from Foxp3-Tg mice, a single transgenic line was chosen. This line (2826) had approximately 16 copies of the transgene and had approximately fivefold higher levels of Foxp3 expression (13, 13a). Although T cell development appears to be normal in these mice, peripheral T cell numbers and representation in secondary lymphoid organs are dramatically decreased. Using a variety of in vitro and in vivo assays, the function of T cells from the Foxp3-Tg mice was shown to have severely decreased responses when activated through the TCR. For example, purified CD4 + T cells displayed dramatically reduced proliferative responses when stimulated in vitro (13). Similarly, these T cells produced virtually no IL-2 upon stimulation. In fact, by any measure, CD4 + T cells from Foxp3-Tg mice were functionally inert. Taken together, these data reflect a generalized deficit in cellular activation of CD4 + T cells that express Foxp3.
The failure of T cells from Foxp3-Tg mice to function in vitro is also reflected in the response of these mice to immunologic challenge in vivo. The Foxp3-Tg mice failed to mount an antigen-mediated contact sensitivity response (13). Also, recent data demonstrate that Foxp3-Tg mice have dramatically depressed responses to T-dependent antigens (14). The latter response appears to be due to a reduced ability to produce cytokines and to elaborate CD40L on their cell surface. + T cells that can suppress the proliferation and cytokine production of TCR-stimulated conventional CD4 + T cells (19, 20) . The role of Foxp3 in these cells has been elucidated in mice through a combination of genetic and direct functional studies. Taken as a whole, these data demonstrate that Foxp3 expression in mouse CD4 + T cells is sufficient to mark these T cells as regulatory. CD25, the IL-2Rα chain, had previously been shown to be the only reliable marker for these cells (19); however, it is also a marker of activated CD4 + T cells. Thus, the identification of Foxp3 as a marker for this population of T cells was critical for the further analysis of these cells and their role in peripheral tolerance.
In addition to the correlation of Foxp3 expression and CD4 Regulation of Foxp3 expression. Although obviously important to the understanding of Treg development, the factors that regulate Foxp3 expression remain elusive. The primary issue that has confounded these studies is that the factors that appear to affect Foxp3 expression also affect the survival and expansion of Tregs. However, some signaling pathways, including CD28, IL-2, and TGF-β, are emerging that appear to have an affect on the expression of Foxp3. For example, recent work has shown that CD28-mediated signals during thymic development are required for proper Foxp3 expression (29). However, other studies have implicated CD28 in Treg survival and expansion (30, 31), complicating an interpretation of the role of CD28 in Foxp3 expression. Similarly, mice lacking the IL-2 pathway owing to targeted mutations also display a deficit in CD4 + CD25 + Tregs. This is true for mice with mutations in il-2, il-2rα, and il-2rβ, as well as for mice lacking the downstream mediator of IL-2 signaling, Stat5 (32-40). However, similar to the situation with CD28, distinguishing between a direct affect on transcription and survival is not possible. Recent studies have shown that IL-2 is absolutely required for Treg expansion in the periphery (41, 42). Furthermore, Malek et al. (39, 40) showed that thymus-restricted expression of IL-2Rβ-chain was sufficient to rescue il-2rb −/− mice from fatal autoimmune disease, demonstrating a need for IL-2 signals during thymic development of Tregs. Finally, using the GFP-Foxp3 strain, Fontenot et al. (21) have shown that thymic expression of Foxp3
is absolutely dependent on TCR-MHC interactions and independent of commitment to either the CD4 or CD8 lineage. A more definitive assessment of the factors that control Foxp3 expression await an analysis of its cis-regulatory region. The availability of the knockin strains described above, as well as a characterization of the Foxp3 cis-regulatory region, will be invaluable in sorting out direct and indirect effects of these and other factors on Foxp3 expression.
Perhaps the most controversial aspect of Foxp3 gene regulation is the role of TGF-β. Although TGF-β can have effects on Treg expansion and survival (43, 44), its actual role is not at all clear. Several groups have shown that in vitro culture of CD4 + CD25 − T cells with a cocktail that includes TGF-β and IL-2, in combination with TCR engagement and costimulation through CD28, can lead to induction of Foxp3 expression and acquisition of repressor activity (45-47). However, there are several issues with these experiments. The cultures used superphysiological concentrations of TGF-β, and investigators have shown that TGF-β can inhibit the proliferative affects of IL-2, at least in conventional T cells (48). Thus, one explanation for the in vitro results is that TGF-β inhibits the proliferation of CD4 + CD25 − Foxp3 − T cells in the cultures, allowing the expansion of contaminating Foxp3
+ cells and an apparent increase in Foxp3 mRNA. Also, the culture systems used are very likely to produce a complex combination of signals in responding cells, making a definitive role for any of the signaling molecules difficult to discern. In support of an indirect role for TGF-β in Foxp3 expression and function, Tregs from mice either lacking TGF-β1 or expressing a dominant-negative TGF-βRII are indistinguishable from their counterparts from wild-type mice in in vitro suppression assays (49).
The data on the in vivo role of TGF-β are equally contradictory. In support of a role for TGF-β in Treg function and Foxp3 expression, several groups have shown that TGF-β is capable of expanding the in vivo pool of Tregs (18). For example, T cellspecific expression of a dominant-active form of TGF-β leads to an elevation in the number of CD4 + CD25 + Tregs and increased Foxp3 expression (50, 51). However, these studies do not differentiate between expansion and de novo generation of Tregs. Using mice with an inducible TGF-β transgene, Peng et al. (44) showed that transient TGF-β expression specifically in the pancreatic islets was sufficient to protect against onset of diabetes. They found that this transient expression increased the number of CD4
+ T cells with a regulatory phenotype in the islets, consistent with a role for TGF-β in the expansion of Tregs in vivo. Studies using mice incapable either of producing TGF-β or of responding to it provide the most contradictory data. These mice have been used to demonstrate that TGF-β is either absolutely required for Treg expansion and function (50, 51) or completely dispensable (49). In addition, recent work has suggested that the effector T cell needs to be TGF-β responsive in order to be suppressed, at least in vivo (52). However, this appears not to be the case in vitro (49; K. Newton & S.F. Ziegler, manuscript in preparation). The recent development of Foxp3 reporter mice should help clarify this issue. In fact, using mice with a reporter for Foxp3 mRNA, Wan & Flavell (22) showed that TGF-β may directly influence Foxp3 expression.
FUNCTIONAL CHARACTERIZATION OF Foxp3
As described above, Foxp3 is a member of the forkhead/winged-helix family of transcriptional regulators. A common feature of members of this family is the FKH domain (Figure 1) , which has been shown to be necessary and sufficient for DNA binding (53, 54). DNA-binding analyses from a number of Fox family proteins have defined a core DNA sequence (5 -A(A/T)TRTT(G/T)R-3 , where R = pyrimidine) surrounded by less conserved sequences (55). Experimentally, two Members of the Fox family are both transcriptional activators and transcriptional repressors. To assess the role of Foxp3 in transcriptional regulation, a reporter plasmid was constructed that contained three copies of the V1P FKH site linked to a minimal SV40 promoter and the firefly luciferase gene. Cotransfection of this reporter plasmid with a Foxp3 expression plasmid into Cos-7 cells resulted in a dramatic reduction of luciferase activity, suggesting that Foxp3 acts as a transcriptional repressor (57). The ability of Foxp3 to act as a transcriptional repressor required the presence of the FKH domain of Foxp3 and the V1P-binding site, showing that binding of Foxp3 to the FKH site is responsible for the observed effect of Foxp3 on the expression of the reporter.
Several lines of evidence suggest that a major target of Foxp3-mediated transcriptional regulation is cytokine genes. For ex-
Other Forkhead Family Proteins and Immune Regulation
In addition to Foxp3, several other members of the forkhead family have been implicated in regulating immune system development and function (90) . For example, mutations in the Foxn1 gene are responsible for the phenotype seen in nude (nu) mice, rats, and humans (91, 92) . These mice are characterized by abnormal development of the epidermis, lack of hair, and absence of a thymus. Mutations in Foxj1 lead to embryonic lethality, but fetal liver chimeras have been used to study its role in the immune system. These mice displayed multisystemic cellular autoimmunity, as well as T cell hyperproliferation and hyperactivity. CD4 + T cells from these animals were skewed toward a Th1 cytokine profile, could be activated solely by IL-2 (CD3 and CD28 stimulation were not required), and exhibited decreased levels of the IκKβ regulatory subunit (93) . These results are consistent with a role for Foxj1 in the negative regulation of NF-κB activity. Finally, Foxo3a has been implicated in cellular survival, where it is involved in the regulation of NF-κB (94, 95) . Upon Aktdependent phosphorylation, Foxo3a is shuttled to cytoplasm and rendered inactive as a transcriptional regulator. Mice deficient in Foxo3a develop T cell hyperactivity and multiorgan lymphocytic infiltrates with age.
ample, ectopic expression of Foxp3 in Jurkat cells resulted in a marked reduction of IL-2 production following stimulation (57). In addition, CD4 + T cells from mice expressing
a Foxp3 transgene were unable to produce IL-2, IL-4, or IFN-γ following TCR-mediated stimulation in vitro and had severely reduced ability to express cytokines in vivo following immunization (13, 14). Taken as whole, these data demonstrate a role for Foxp3 in the negative regulation of cytokine gene expression in CD4 + T cells. Inspection of composite NFAT/AP-1 sites upstream of several cytokine genes revealed a possible explanation for the ability of Foxp3 to regulate these genes. Either overlapping or directly adjacent to these DNA-binding sites was a potential FKH-binding site. Provocatively, oligonucleotide probes containing the composite sites from the human IL-2 and GM-CSF genes were capable of competing with the V1P site for Foxp3 binding in a gel shift assay (57). Confirmation of the ability of Foxp3 to repress NFAT-mediated transcription comes from experiments using a reporter plasmid consisting of the -280 composite NFAT/AP-1 site from the mouse IL-2 gene. NFAT activation was inhibited when the Foxp3 expression vector was cotransfected (57). Furthermore, work from our laboratory, using a bipartite reporter containing both NFAT and GAL4 DNA-binding sites, has shown that Foxp3 can inhibit NFAT-mediated transcription while binding to a more distant DNA site ( J. Lopes, T. Torgerson, L.A. Schubert, H. Ochs, and S.F. Ziegler, manuscript submitted). These experiments took advantage of fusion proteins consisting of the yeast GAL4 DNA-binding domain fused to the non-FKH sequences from FOXP3, which was found to be capable of inhibiting activation-induced expression of the NFAT reporter.
Much effort is currently being used to define functional domains within FOXP3. As shown in Figure 1 , FOXP3 contains at least three distinct structural domains: FKH, Leucine zipper, and C2H2 zinc finger. As described above, the FKH domain is critical for both DNA binding and for nuclear localization. Confirmation of its role in nuclear localization comes from site-directed mutation of two lysine residues (K415 and K416), at the carboxy end of the FKH domain, to glutamic acid. This mutant form of FOXP3, when expressed in cell lines, is localized to the cytoplasm ( J. Lopes, T. Torgerson, L.A. Schubert, H. Ochs, and S.F. Ziegler, manuscript submitted).
The
The amino terminal half of FOXP3 contains no obvious identifiable functional domains, although it does contain a fairly high proportion of proline residues (Figure 1) . However, we have shown that a fusion protein containing the DNA-binding domain of the yeast transcription factor GAL4 and the amino terminal half of human FOXP3 (amino acids 1-198) was functional as a transcriptional repressor, whereas a fusion of the zinc finger and Leucine zipper domains was nonfunctional (the GAL4 DNA-binding domains also contain nuclear localization and dimerization sequences). Using infection of primary T cells with FOXP3 deletion mutants, Bettelli et al. (11) showed that there were two functional domains within the amino terminal 200 amino acids of Foxp3, one between amino acids 1 and 150, and one between amino acids 150 and 200. Our lab has also defined two functional domains with the amino terminus of Foxp3. One domain, between amino acids 67 and 132, is involved in general transcriptional repression by FOXP3. The second, between amino acids 135 and 198, is specifically required for repression of NFAT-mediated transcription. Bettelli et al. (11) also showed that Foxp3 can directly interact with NFAT and the NF-κB subunit P65. Although the region of interaction with Foxp3 was not identified, that data described above would predict that the region between amino acids 135 and 198 is involved.
HUMAN FOXP3: NOT QUITE THE SAME AS MOUSE
The identification of Foxp3 as the gene mutated in scurfy mice led to an investigation of its possible role in a human syndrome with clinical features similar to those seen in scurfy animals. This syndrome, known as IPEX (immune dysfunction/polyendocrinopathy/ enteropathy/X-linked), was first characterized in 1982 and subsequently mapped to the X chromosome (60, 61) . It is characterized by watery, sometimes bloody, diarrhea in very early infancy. In addition, nearly all affected males develop dermatitis (usually eczematous in nature), and most cases develop autoimmune endocrinopathies, with type 1 diabetes and thyroiditis the most common. In general, affected individuals develop symptoms very early in infancy and usually die in the first two years of life (61) (62) (63) (64) .
The similarity of the phenotypes of scurfy mice and IPEX humans suggested a common cause for the two diseases. Indeed, mutations in FOXP3 have been identified in over 20 families with affected offspring (62, (65) (66) (67) (68) (69) . Many of these are missense mutations in the FKH domain, but mutations have been found across the length of the gene (Figure 1) . However, not all patients diagnosed with IPEX have FOXP3 mutations. Sequencing of the FOXP3 gene in a large cohort of individuals diagnosed with IPEX revealed identifiable coding region mutations in 60%, with an additional 10% having dramatically reduced mRNA levels (65) . One interpretation of these data is that a mutation in FOXP3 leads to development of IPEX, and those IPEX patients without FOXP3 mutations may be mutations in genes whose products interact with FOXP3, either physically or functionally. Indeed, a recent study has found a patient with IPEX-like IPEX: immune dysfunction/polyendocrinopathy/ enteropathy/ X-linked symptoms for whom FOXP3 was ruled out as a candidate gene (66) .
As shown in Figure 1 + CD25 + FOXP3 + T cells did not affect the proliferation of T cells when stimulated with an unrelated antigen, tetanus toxoid, unless they also were given the HA peptide. Thus, they required cognate antigen for activation, but once activated they were capable of suppressing responses in an antigennonspecific manner.
The data outlined above suggest that there are at least two distinct populations of Tregs in humans. One population is generated in the thymus, is self-reactive, and is involved in protection from autoimmune responses. These Tregs are referred to as natural Tregs and would be analogous to those seen in the mouse that arise during thymic selection (83) . The role of this population of Tregs is to protect against self-reactive effector T cells in the periphery. These cells comprise the CD4 + CD25 + T cell population in human peripheral blood and are equivalent to those Tregs described in the mouse. This population of Tregs is also likely to be most affected by the mutations in FOXP3 seen in IPEX patients. These mutations can be expected to result either in the development of self-reactive T cells that lack suppressor activity or in the complete lack of this population altogether. In either instance, the result would be a failure in the ability to control self-reactive effector T cells. In this respect, the IPEX patients resemble the scurfy mice.
A suppress is IL-10 and TGF-β independent, but is contact dependent (18). In addition, transcript array analysis has shown that the same set of genes regulated in natural Tregs appears to be similarly regulated in the in vitro-generated cells (P. Putheti & S.F. Ziegler, unpublished data). Taken together, the data demonstrate that CD4 + T cells with the same functional properties as thymically derived Tregs can be generated from naive conventional CD4
+ T cells following TCR stimulation. Although the in vivo function of these cells is not known, we propose that they play a role in controlling immune responses, possibly serving to limit bystander activation at the site of the response. In addition, there are reports that CD4 + CD25
+
Tregs can induce infectious tolerance through the local generation of classes of regulatory T cells (e.g., Tr1 cells) (84), further extending this paradigm. An unanswered question at this point is the fate of the induced Tregs. Because these cells appear to respond poorly to proliferative signals and are impaired in cytokine production, it seems likely that they will not persist once the response has ended and antigen is no longer available.
FOXP3 AND THERAPEUTIC INTERVENTION FOR AUTOIMMUNITY
As described above, following retroviralmediated introduction of Foxp3, conventional CD4 + T cells acquire a regulatory-like phenotype and are capable of suppressing immune responses both in vitro and in vivo (15-17). The in vivo experiments involved cotransfer of Foxp3-transduced T cells with pathogenic CD4
+ T cells in a model of colitis. These studies suggest the possibility of using ectopic Foxp3 expression to convert T cells to take on a regulatory phenotype and then using these cells in adoptive cellular immunotherapy. Coupled with the ability to identify and isolate antigen-specific human CD4 + T cells using MHC class II tetramers (85-87), ex vivo generation of antigen-specific Tregs has great promise. Indeed, some recent reports have suggested that this approach may be viable. For example, Jaeckel et al. (27) used Foxp3-transduced T cells from BDC2.5 TCR transgenic mice to treat NOD mice with recent onset diabetes. They found that the antigen-specific BDC2.5 T cells, expressing Foxp3, were capable of reversing disease. However, they also showed that transfer of Foxp3-transduced polyclonal T cells from NOD mice failed to rescue. These data suggest that the critical feature for this type of therapy may be getting enough antigenspecific Tregs to the correct site, and that the transduced polyclonal T cells did not contain sufficient islet-antigen-specific cells to have a therapeutic effect.
In contrast to that study, Loser et al. (88) have shown that Foxp3-transduced polyclonal naive T cells, when transferred to sensitized hosts, could inhibit contact hypersensitivity responses. These polyclonal T cells were also used to treat mice expressing a keratin 14-CD40L transgene. These mice develop chronic skin inflammation and systemic autoimmunity (89) . Transfer of Foxp3-transduced CD4 + T cells into these animals protected against both the local skin inflammation and the systemic autoimmunity (88) .
Transferring these types of therapies to humans presents unique problems. As described above, stimulation of human CD4 + CD25 − T cells induces FOXP3 expression, and most methods for introducing foreign genes into T cells using viral vectors require some level of stimulation. Thus, the very cells one may want to transduce and convert to Tregs may be less likely to be infected owing to expression of FOXP3 and a lowered overall activation level. However, the work from Walker et al. (82) suggests that deriving antigen-specific CD4 + T cells in vitro with self-antigens, followed by isolation of CD25 + that are also MHC class II tetramer + , may be a solution to this problem. The obvious limitation to this approach is the availability of the appropriate MHC class II tetramer for a given HLA haplotype and specific epitope.
In summary, the reemergence of suppressor T cells and the discovery of FOXP3 as a critical player in their development and function hold great promise for the treatment of autoimmune diseases in humans. The differences between humans and mice may present obstacles in the transfer from mouse models to actual human disease. Thus, a more concerted effort to develop better human in vitro and in vivo systems is required to understand better the potential therapeutic benefits of manipulating FOXP3.
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